İmmünsüpresif İlaçlar ve HBV Reaktivasyonu

Year 2022, Volume: 11 Issue: 1, 173 - 183, 29.04.2022

Betül Ersöz Acar

https://doi.org/10.47493/abantmedj.1051982

Abstract

Dünyada iki milyardan fazla insanın Hepatit B virüsü(HBV) ile enfekte olduğu tahmin edilmektedir. Hepatit B virüs reaktivasyonu(HBVr), immünsüpresif tedaviden sonra potansiyel olarak ölümcül olabilen bir komplikasyondur. İmmünsupresif tedavi görenlerde, HBV reaktivasyon riski, HBV enfeksiyonunun durumuna ve kullanılan ilacın immünsüpresif etkinlik derecesine göre değişmektedir. İmmünsüpresif tedaviye bağlı HBVr önlenebilir bir durum olduğundan, hangi hastaya nasıl ve ne zaman antiviral ilaç tedavisi verileceği önemlidir. Bu nedenle bu derlemede, HBVr ile ilgili risk gruplarının belirlenmesi ve antiviral tedavi yönetim stratejilerinin literatür eşliğinde gözden geçirilmesi amaçlanmıştır.

Keywords

Hepatit B virüsü, Reaktivasyon, Profilaksi

Immunsupressive Drugs and HBV Reactivation

Abstract

It is estimated that more than two billion people worldwide are infected with the Hepatitis B Virüs(HBV). Hepatitis B virüs reactivation(HBVr) is a potentially fatal complication after immunosuppressive therapy. The risk of HBV reactivation in those receiving immunosuppressive therapy varies according to the status of HBV infection and the degree of immunosuppressive effectiveness of the drug used. Since HBVr due to immunosuppressive therapy is a preventable condition, it is important how and when antiviral drug treatment will be given to which patient. Therefore, in this review, it is aimed to determine the risk groups related to HBVr and to review the antiviral treatment management strategies in the current literatüre.

Keywords

Hepatitis B Virus, Reactivation, Prophylaxis

References

• Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49:156-65.
• Galbraith RM, Eddleston AL, Williams R, et al. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2:528-30.
• Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-22.
• Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virüs(HBV) reactivation in cancer patient undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90:1306-11.
• Shouval D, Shibolet O. Immunsupression and HBV reactivation. Semin Liver Dis 2013; 33:167-77.
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560-99
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int 2016; 10:1-98
• Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institıte Guideline on the Prevention and Treatment of Hepatitis B virüs Reactivation During Immunsupresive Drug Therapy. Gastroenterology 2015; 148:215-19.
• Europen Association fort he Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virüs infection. J Hepatol 2017; 67:370-98.
• Ganem D, Prince AM. Hepatitis B virüs infection-natural history and clinical consequences. N Eng J Med 2014; 350:1118-29.
• Ferrari C. HBV and İmmune response. Liver Int 2015; suppl 1: 121-128.
• Perillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virüs reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:221-44.
• Tiede I, Fritz G, Strand S, et al. CD28 dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes. J Clin Invest 2003; 111:1133-45.
• Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virüs infection after discontinuation of low döşe methotrexate therapy. Ann Intern Med 1990; 112:381-2.
• Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virüs in patient with rheumatoid arthritis who recieved immunosuppressive therapy: evaluation of both HBsAg positive and HBsAg negative cohorts. J Gastroenterol 2011; 46:556-64.
• Schalm SW, Summerskill WH, Gitnick GL, et al. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B S antigen. Gut 1976; 17:781-6.
• Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognises a specific nucleotide sequence in hepatitis B virüs DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630-3.
• Hoofnagle JH, Davis GL, Pappas SC, et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1986; 104:12-7.
• Kim TW, Kim MN, Kwon JW, et al. Risk of hepatitis B virüs reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology 2010; 15:1092-7.
• Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virüs infections and anti- tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 9:1366-71.
• Ye H, Zhang XW, Mu R, et al. Anti TNF Therapy in patients with HBV İnfection- analysis of 87 patients with inflammatory arthritis. Clin Rheumatol 2014; 1: 119-23.
• Lee YH, Bae SC, Song GG. Hepatitis B virüs(HBV) reactivation in rheumatic patients with hepatitis core antigen( HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31:118-21.
• Jennings JJ, Mandaliva R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including currunt and alternative management strategies. Expert Opin Drug Metab Toxicol 2019; 15(3):231-44.
• Lleo A, Rimasa L, Colombo M. Hepatotoxicity of immune check point inhibitors: aproach and management. Dig Liver Dis 2019; 51(8)1074-8.
• Zhang X, Zhou Y, Chen C, et al. Hepatitis B virüs reactivation in cancer patients with positive hepatitis B surface antigen undergouing PD-1 inhibition. J Immunother Cancer 2019; 7(1)322.
• Pu D, Yin L, Zhou Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advaced stage cancer: asystematic review. Medicine 2020; 99(5):e19013.
• Shah NJ, Al-Shbool G, Blacburn M, et al. Safety and efficacy of immune check point inhibitors(ICIs) in cancer patients with HIV, Hepatitis B, or Hepatitis C viral infection. J Immunother Cancer 2019; 7(1):353.
• Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013; 310:1664.
• Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virüs(HBV) reactivation in non-Hodgkin lymphoma patients recieving rituksimab- chemotherapy: a meta-analysis. J clin Virol. 2013; 57(3):209-14.
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virüs exposure undergoing rituksimab containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32:3736-43.
• Mikulska M, Nicolini L, Signori A, et al. Hepatitis B reactivation in HBsAg negative/HBcab positive allogenic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014; 20:694-701.
• Reddy NM, Savani BN. Hepatitis B reactivation in patients with Hematological Malignancies and Stem Cell Transplantation. J Blood Lymph 2013; 4:114.
• Pattulo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 2016; 22:219-37.
• Hwang JP, Somerfield MR, Alston-Johnson DE,et al. Hepatitis B virüs Screening for patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 2015; 33:2212-20.
• Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert rev Gastroenterol Hepatol 2011; 5:323-39.
• Lok AS, Lai CL, Leung N, et al. Long term safety of Lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-22.
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18:877-83.
• Pattulo V. Hepatitis B reactivation in the setting of chemoteherapy and immunosuppression prevention is better than cure. World J Hepatol 2015; 7:954-67.
• Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post Chemotherapy for lymphoma in a hepatitis B surface antigen negative, hepatitis B core antibody positive patient: potential implication for future prophylaxis recommendations. Leuk Lymphoma 2005; 46:1085-9.
• Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomised trial. Hepatology 2008; 47: 844-53.